Nhận xét kết quả điều trị cầm máu của bệnh nhân hemophilia được phẫu thuật chỉnh hình quản lý tại Viện Huyết học - Truyền máu Trung ương giai đoạn 2013 – 2023=Comment on the results of hemostatic treatment in hemophilia patients undergoing orthopedic surgery managed at the National Institute of Hematology and Blood Transfusion from 2013

Nhận xét kết quả điều trị cầm máu của bệnh nhân hemophilia được phẫu thuật chỉnh hình quản lý tại Viện Huyết học - Truyền máu Trung ương giai đoạn 2013 – 2023=Comment on the results of hemostatic treatment in hemophilia patients undergoing orthopedic surgery managed at the National Institute of Hematology and Blood Transfusion from 2013 - 2023

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Xuân Thành Đào, Minh Thuận Đồng, Thị Mai Nguyễn, Văn Nghi Nguyễn, Thị Kiều My Trần, Thị Mỹ Dung Trần, Thị Phương Trần, Thị Quyên Trần

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.705-714

Bộ sưu tập: Metadata

ID: 478351

Thêm vào giỏ

Nhận xét kết quả điều trị cầm máu của nhóm bệnh nhân hemophilia được phẫu thuật chỉnh hình. Đối tượng và phương pháp nghiên cứu: 52 bệnh nhân, mô tả loạt ca bệnh, hồi cứu. Kết quả: Tuổi trung bình 30,65 ± 13,57, chủ yếu trong độ tuổi lao động. Tỷ lệ hemophilia A/B là 5/1. Có 23,1% bệnh nhân trong nhóm nghiên cứu có tổn thương trước mổ là thoái hóa khớp. 2 trường hợp chiếm 3,8% có ức chế yếu tố VIII trước mổ. Phẫu thuật lớn chiếm 80,8%, trong đó 29,6% phẫu thuật chỉnh hình, 19,2% phẫu thuật kết hợp xương. Có 96,2% bệnh nhân được phẫu thuật một lần. 73,1% bệnh nhân dùng yếu tố cô đặc trước mổ. Lượng chế phẩm trung bình sử dụng trong và sau mổ với hemophilia A là 474,9 ± 449 IU/kg và hemophilia B là 317,4 ± 292,6 IU/kg. 76,9% không có biến chứng sau mổ. Đa số bệnh nhân có kiểm soát đông máu cuộc mổ rất tốt. 2 trường hợp chiếm 4% xuất hiện chất ức chế yếu tố VIII sau mổ. Số ngày nằm viện trung bình với hemophilia A là 29,6 ± 19,3 ngày và hemophilia B là 23,4 ± 15,1 ngày.To evaluate the hemostatic treatment outcomes of hemophilia patients undergoing orthopedic surgery. Subjects and research methods: 52 patients, descriptive case series, retrospective study. Results: The average age was 30.65 ± 13.57, mainly in the working age group. The ratio of hemophilia A/B was 5/1. 23.1% of patients in the study group had preoperative lesions due to joint degeneration. 2 cases, accounting for 3.8%, had factor VIII inhibitors preoperatively. Major surgeries accounted for 80.8%, of which 29.6% were orthopedic surgeries and 19.2% were bone fixation surgeries. 96.2% of patients underwent surgery once. 73.1% of patients used clotting factor concentrates preoperatively. The average amount of products used during and after surgery for hemophilia A was 474.9 ± 449 IU/kg and for hemophilia B was 317.4 ± 292.6 IU/kg. 76.9% had no postoperative complications. The majority of patients had very good control of hemostasis during the surgery. 2 cases, accounting for 4%, developed factor VIII inhibitors postoperatively. The average length of hospital stay for hemophilia A was 29.6 ± 19.3 days and for hemophilia B was 23.4 ± 15.1 days.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR